Manager TitleAgeSince
Chief Executive Officer 64 2022-03-30
Director of Finance/CFO - 2024-07-31
Director TitleAgeSince
Chairman 70 2019-11-19
Director/Board Member 65 2013-05-31
Director/Board Member 80 2021-12-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/22/22 Free 111,193 0.2314%
1/19/21 Sell 1 0.0000%
1/19/21 Sell 2,000 0.0179%
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-.--% - - 817K
-1.00%+0.41%+41.86%-5.58% 78.69B
+2.08%+29.11%+708.13%+102.59% 79.4B
-1.21%+0.77%-10.63%-30.06% 59.52B
-1.80%-2.29%-13.07%+28.02% 46.53B
+1.18%+3.03%+9.11%+169.01% 46.58B
+0.55%+5.61%+67.76%-10.75% 33.63B
-0.44%-1.13%+51.71%+110.88% 25.11B
-0.10%+3.21%+4.89%+155.64% 22.13B
+0.05%-2.42%+57.59%+97.38% 15.31B
Average -7.82%+4.05%+101.93%+68.57% 45.21B
Weighted average by Cap. -0.51%+6.45%+155.49%+55.18%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
50
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SPEX Stock